Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035015 | 0.94 | CA1 (0.45) | CA2CA1EPHX1SLC1A2SLC1A1 | |
| SCHEMBL27728959 | 0.92 | EPHX1 (0.47) | CA2CA1EPHX1TP53 | |
| SCHEMBL14546504 | 0.86 | CA1 (0.40) | CA2CA1EPHX1SLC15A1SLC1A3 | |
| SCHEMBL15416197 | 0.86 | CA1 (0.40) | CA2CA1EPHX1SLC15A1SLC1A3 | |
| SCHEMBL7316786 | 0.84 | CA2 (0.54) | CA2CA1EPHX1SLC15A1MAPK1 | |
| SCHEMBL7325930 | 0.84 | CA2 (0.54) | CA2CA1EPHX1SLC15A1MAPK1 | |
| SCHEMBL9831486 | 0.84 | CA2 (0.54) | CA2CA1EPHX1SLC15A1MAPK1 | |
| SCHEMBL4391098 | 0.80 | CA2 (0.54) | CA2CA1EPHX1FDPS | |
| SCHEMBL27539980 | 0.79 | CA2 (0.48) | CA2CA1EPHX1SLC15A1MAPK1 | |
| SCHEMBL4023785 | 0.78 | CA1 (0.47) | CA2CA1EPHX1MAPK1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | claimed |
| CN-102952064-A | Preparation method of medicine intermediate cis-ex-bicyclo[2.2.1]heptane-2.3-dicarboximide | TIANJIN INST PHARM RESEARCH | 2013-03-06 | — | — | CN | claimed |
| CN-101362751-B | Tandospirone citrate, preparation method thereof, formulations and quality control method | CHENGDU KERUIDE PHARMACEUTICAL INVEST LTD | 2011-05-11 | — | — | CN | claimed |
| CN-101362751-A | Tandospirone citrate, preparation method thereof, formulations and quality control method | CHENGDU LVKAI PHARMACEUTICAL T (CN) | 2009-02-11 | — | — | CN | claimed |
| CN-115611866-B | Preparation method of tandospirone citrate | 南京海纳医药科技股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | disclosed |
| CN-115611866-A | Preparation method of tandospirone citrate | 南京海纳医药科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-2563791-A1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-03-06 | — | — | EP | disclosed |
| CN-102952064-A | Preparation method of medicine intermediate cis-ex-bicyclo[2.2.1]heptane-2.3-dicarboximide | TIANJIN INST PHARM RESEARCH | 2013-03-06 | — | — | CN | disclosed |
| WO-2011136384-A1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-03 | — | — | WO | disclosed |
| CN-101362751-B | Tandospirone citrate, preparation method thereof, formulations and quality control method | CHENGDU KERUIDE PHARMACEUTICAL INVEST LTD | 2011-05-11 | — | — | CN | disclosed |
| CN-101362751-A | Tandospirone citrate, preparation method thereof, formulations and quality control method | CHENGDU LVKAI PHARMACEUTICAL T (CN) | 2009-02-11 | — | — | CN | disclosed |